RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raises the price target from $28 to $33.
July 14, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals' price target has been raised from $28 to $33 by RBC Capital, maintaining an Outperform rating.
The news of RBC Capital raising the price target for ACADIA Pharmaceuticals and maintaining an Outperform rating is likely to have a positive impact on the company's stock in the short term. Investors may see this as a sign of confidence in the company's future performance, potentially leading to increased demand for the stock and a rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100